Larazotide
Also known as: AT-1001, Larazotide Acetate
Tight junction regulator derived from Zonula occludens toxin; reduces intestinal permeability ("leaky gut") by restoring tight junction integrity.
- Typical dose
- 250 mcg – 1 mg
- Frequency
- three times daily
- Route
- Oral
- Half-life
- 1.5 hours
- Routes
- Oral
- Status
- Phase III discontinued (Sept 2023); celiac program ended
Benefits
- Reduces intestinal permeability
- Celiac disease symptom relief
- Gut barrier restoration
- Leaky gut support
Dosing
A common research range for Larazotide is 250 mcg to 1 mg three times daily. Oral; take before meals; investigational. These figures are reference points from published literature, not a prescription — your protocol should be set with a licensed provider.
Half-life
Larazotide has an approximate half-life of 1.5 hours. Vial can display informational half-life estimates when supported data is available. These estimates are not measured blood concentrations or dosing instructions.
Storage
Room temperature.
Reported side effects
- Headache
- GI discomfort
- Urinary tract infection (trial data)
Commonly stacked with
Track Larazotide with Vial
Vial logs every Larazotide dose, organizes your schedule, and offers reconstitution math and supported half-life estimates. Tracking records stay on your device. A Vial Pro subscription is required. Download Vial on the App Store →
This page is for educational and harm-reduction purposes only. Larazotide is not FDA-approved for most uses described here. Always consult a licensed physician before starting any peptide protocol. Vial does not sell peptides, recommend vendors, or provide medical advice.